CPHI vs. LGVN, PCSA, SEEL, THAR, GNPX, XCUR, CING, LIPO, PTPI, and NEXI
Should you be buying China Pharma stock or one of its competitors? The main competitors of China Pharma include Longeveron (LGVN), Processa Pharmaceuticals (PCSA), Seelos Therapeutics (SEEL), Tharimmune (THAR), Genprex (GNPX), Exicure (XCUR), Cingulate (CING), Lipella Pharmaceuticals (LIPO), Petros Pharmaceuticals (PTPI), and NexImmune (NEXI). These companies are all part of the "pharmaceutical preparations" industry.
Longeveron (NASDAQ:LGVN) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, community ranking, dividends and earnings.
10.0% of Longeveron shares are held by institutional investors. 24.3% of Longeveron shares are held by company insiders. Comparatively, 46.0% of China Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Longeveron has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, China Pharma has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.
In the previous week, Longeveron had 6 more articles in the media than China Pharma. MarketBeat recorded 8 mentions for Longeveron and 2 mentions for China Pharma. China Pharma's average media sentiment score of 0.65 beat Longeveron's score of 0.46 indicating that Longeveron is being referred to more favorably in the media.
Longeveron currently has a consensus target price of $12.00, suggesting a potential upside of 599.71%. Given China Pharma's higher possible upside, analysts plainly believe Longeveron is more favorable than China Pharma.
China Pharma has higher revenue and earnings than Longeveron.
China Pharma has a net margin of -43.91% compared to China Pharma's net margin of -3,020.17%. Longeveron's return on equity of -54.53% beat China Pharma's return on equity.
Longeveron received 7 more outperform votes than China Pharma when rated by MarketBeat users. Likewise, 87.50% of users gave Longeveron an outperform vote while only 0.00% of users gave China Pharma an outperform vote.
Summary
Longeveron beats China Pharma on 8 of the 15 factors compared between the two stocks.
Get China Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPHI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
China Pharma Competitors List
Related Companies and Tools
